Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1733)

Abstract

MicroRNA (miRNA) is the noncoding gene: therefore, the miRNA gene inheritably controls protein gene expression through transcriptional and post-transcriptional levels. Aberrant expression of miRNA genes causes various human diseases, especially cancers. Although cancer is a complex disease, cancer/miRNA implication has yet been grasped from the perspective of miRNA profile in bed side. Since miRNA is the mobile genetic element, the clinical verification of miRNA in microvesicle of blood is too much straggle to predict potential cancer/miRNA associations without bioinformatical computing. Further, experimental investigation of miRNA/cancer pathways is expensive and time-consuming. While the accumulated data (big data) of miRNA profiles has been on line as the databases in cancers, using the database algorithms for miRNA target prediction have reduced required time for conventional experiments and have cut the cost. Computational prediction of miRNA/target mRNA has shown numerous significant outcomes that are unobtainable only by experimental approaches. However, ID of miRNA in the annotation is an arbitrary number and the ID is not related with miRNA its functions. Therefore, it has not been physicochemically shown why multiple miRNAs in blood or tissues are useful for diagnosis and porgnosis of human diseases or why function of single miRNA in cancer is rendered to oncomir or tumopr suppressor. In addition, it is less cleared why environmental factors, such as temperature, radiation, therapeutic anti-cancer immune or chemical agents can alter the expression of miRNAs in the cell. The ceRNA theory would not be enough for the investigation of such subjects. Given miRNA/target prediction tools, to elucidate such issues with computer simulation we have previously introduced the quantum miRNA/miRNA interaction as a new scoring using big database. The quantum score was implicated in miRNA synergisms in cancer and participated in the miRNA/target interaction on human diseases. On the other hand, ribosomal RNA (rRNA) is the dominant RNA species of the cells. It is well known that ribosomopathies, such as Diamond-Blackfan anemia, dyskeratiosis congenital, Shwachman-Diamond syndrome, 5q-myelodysplastic syndrome, Treacher Collins syndrome, cartilage-hair hypoplasia, North American Indian childhood cirrhosis, isolated congenital asplenia, Bowen-Conradi syndrome and cancer are caused by altered expression of ribosomal proteins or rRNA genes. We have proposed the hypothesis that the interaction among miRNAs from rRNA and/or other cellular miRNAs would be involved into cancer as the ribosomopathy. Subsequently, we found rRNA-derived miRNAs (rmiRNAs) by using the sequence homology search (miPS) with miRNA database (miRBase). Further, the pathway related with cancer between rmiRNA/target protein gene was predicted by miRNA entangling target sorting (METS) algorithm. In this chapter, we describe about the usage of in silico miRNA identification program, miRNA/target prediction search through the database and quantum language of miRNA by the METS, and the ontology analysis. In particular, the METS algorithm according to the quantum value would be useful simulator to discover a new therapeutic target aganist cancer. It may also partly contribute to the elucidation of complex mechanisms and development of agents of anti-cancer.

Key words

AluRNA Big data Biomarker Cancer microRNA Quantum Ribosomal RNA 

References

  1. 1.
    Fujii YR (2017) The microRNA 2000: from HIV-1 to healthcare. Scientific Research Publishing, Paseo Segovia Irvine, CAGoogle Scholar
  2. 2.
    Tang S, WK W, Li X, Wong SH, Wong N, Chan MT, Sung JJ, Yu J (2016) Stratification of digestive cancers with different pathological features and survival outcomes by microRNA expression. Sci Rep 6:24466CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Fujii YR (2010) RNA genes: retroelements and virally retroposable microRNAs in human embryonic stem cells. Open Virol J 4:63–75CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fujii YR (2013) The RNA gene information: retroelement-microRNA entangling as the RNA quantum code. Methods Mol Biol 936:47–67CrossRefPubMedGoogle Scholar
  5. 5.
    Fujii YR (2009) Oncoviruses and pathogenic microRNAs in humans. Open Virol J 3:37–51CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Stults DM, Killen MW, Pierce HH, Pierce AJ (2008) Genomic architecture and inheritance of human ribosome RNA gene clusters. Genome Res 18:13–18CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Henras AK, Plisson-Chastang C, O'Donohue MF, Chakraborty A, Gleizes PE (2015) An overview of pre-ribosomal RNA processing in eukaryotes. RNA 6:225–242PubMedGoogle Scholar
  8. 8.
    Lafontaine DLJ, Tollervey D (2001) The function and synthesis of ribosomes. Nat Rev Mol Cell Biol 2:514–520CrossRefPubMedGoogle Scholar
  9. 9.
    Luft F (2010) The rise of a ribosomopathy and increased cancer risk. J Mol Med 88:1–3CrossRefPubMedGoogle Scholar
  10. 10.
    Montanaro L, Trere D, Derenzini M (2008) Nucleolus, ribosomes, and cancer. Am J Pathol 173:301–310CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Brighenti E, Tere D, Derenzini M (2015) Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility? Oncotarget 6:38617–38627CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Liang XH, Crooke ST (2011) Depletion of key protein components of the RISC pathway impairs pre-ribosomal RNA processing. Nucleic Acids Res 39:4875–4889CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Caudron-Herger M, Pankert T, Seiler J, Nemeth A, Voit R, Grummt I, Rippe K (2015) Alu element-containing RNAs maintain nucleolar structure and function. EMBO J 34:2758–2774CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Riffo-Campos A, Riquelme I, Brebi-Mieville P (2016) Tools for sequence-based miRNA target prediction: what to choose? Int J Mol Sci 17:E1987CrossRefPubMedGoogle Scholar
  15. 15.
    Yoshikawa M, Osone T, Fujii YR (2016) MicroRNA memory I: the positive correlation between synergistic effects of microRNAs in cancer and a novel quantum scoring system. J Adv Med Phar Sci 5(4):1–16Google Scholar
  16. 16.
    Osone T, Yoshikawa M, Fujii YR (2016) MicroRNA memoryII: a novel scoring integration model for prediction of human disease by microRNA/microRNA quantum multi-interaction. J Adv Med Pharm Sci 5(4):1–18Google Scholar
  17. 17.
    Yu H, Chen X, Lu L (2017) Large-scale prediction of microRNA-disease associations by combinatorial prioritization algorithm. Sci Rep 7:43792CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    You ZH, Huang ZA, Zhu Z, Yan GY, Li ZW, Wen Z, Chen X (2017) PBMDA: a novel and effective path-based computational model for miRNA-disease association prediction. PLoS Comput Biol 13:e1005455CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yoshikawa M, Fujii YR (2016) Human ribosomal RNA-derived resident microRNAs as the transmitter of information upon the cytoplasmic cancer stress. Biomed Res Int 2016:7562085CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Anas JI, Menendez P, Andres-Leon E, Gomez-Lopez G, Yanowsky K, Calvete-Candenas J, Inglada-Perez L, Martinez-Delgado B, Benitez J (2015) Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem 61:1098–1106CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Retroviral Genetics Group, Pharmaco-MicroRNA GenomicsGraduate School of Pharmaceutical Sciences, Nagoya City UniversityNagoyaJapan

Personalised recommendations